Dr. Reddy's

Dr. Reddy’s Laboratories Limited (REDY) – New product launches lead the performance

in , , on December 7, 2022

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.

Dr. Reddy’s Laboratories Limited (REDY)

REDY’s performance is also impressive due to its strong performance of gross margin. The favourable product mix of the company has helped to achieve the growth in margin.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages : 35

Release Information

  • Price
    :

    $99.00

  • Released
    :

    December 7, 2022

  • Last Updated
    :

    December 8, 2022